SCHEMBL23948567

SCHEMBL23948567

CC(C)(C)OC(=O)N(Cc1ccccc1)C1CC(CO)C(CO)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.53
CETP P11597 2/20 0.44
JAK2 O60674 1/20 0.43
JAK1 P23458 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
NCOR2 Q9Y618 1/20 0.43
AKT1 P31749 3/20 0.41
CTSL P07711 2/20 0.40
CTSB P07858 2/20 0.40
CTSS P25774 2/20 0.40
KDM1A O60341 3/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
NR1H4 Q96RI1 1/20 0.38
OPRM1 P35372 1/20 0.38
KMT2A Q03164 1/20 0.37
CTSD P07339 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL895157 0.86 HSD11B1 (0.53) HSD11B1CETPJAK2JAK1HDAC3
SCHEMBL10207431 0.84 HSD11B1 (0.56) HSD11B1JAK2JAK1HDAC3HDAC1
SCHEMBL20683494 0.84 HSD11B1 (0.52) HSD11B1CETPJAK2JAK1HDAC3
SCHEMBL23925067 0.84 HSD11B1 (0.54) HSD11B1CETPJAK2JAK1HDAC3
SCHEMBL6980390 0.82 CTSD (0.53) HSD11B1CETPJAK2JAK1HDAC3
SCHEMBL27884072 0.82 AGER (0.54) HSD11B1JAK2JAK1HDAC3HDAC1
SCHEMBL20243405 0.81 HSD11B1 (0.49) HSD11B1CETPJAK2JAK1HDAC3
SCHEMBL14675151 0.81 HSD11B1 (0.53) HSD11B1CETPJAK2JAK1HDAC3
SCHEMBL14675152 0.81 HSD11B1 (0.53) HSD11B1CETPJAK2JAK1HDAC3
SCHEMBL15820253 0.80 HSD11B1 (0.53) HSD11B1CETPJAK2JAK1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) 2023-06-01 US disclosed
EP-4137491-A1 IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) 2023-02-22 EP disclosed
EP-4137491-A1 IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) 2023-02-22 EP disclosed
WO-2021209055-A1 IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE 成都百裕制药股份有限公司 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF SYMPK, PAICS, CYP2C9 HSD11B1 418/4885CETP 3004/4885JAK2 537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.